Dr. Timothy Paul De Stigter, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 216 Main Street, Aurelia, IA 51005 Phone: 712-434-2023 |
News Archive
Cedars-Sinai neurosurgeons have begun using a high-definition imaging device to see inside the brain during surgery, allowing them to map safer pathways to reach and remove tumors.
Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.
The Florida Society of Pain Management Providers, applauds Senate President Mike Haridopolos, Senator Mike Fasano and Attorney General Pam Bondi for their support of the Prescription Drug Monitoring Program and their united opposition to the attempt to repeal the program.
Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.
› Verified 8 days ago